

## THE SIDE EFFECT OF NORISTERAT INJECTION IN SOME BIOCHEMISTRY PARAMETERS IN AL-DIWANIYA CITY

Ali Noory Fajer\*, Haider Khabt Aboud\*\*, Noor Essam Abdul Rezaq \*\*\*

\*Dep. of Biology, Education College, Al- Qadisiyah University, Iraq. \Ali.fajer@qu.edu.iq  
Dep. of Biology, Education College, Samarra University, Iraq\*\*\*

Article received 2.8.2018, Revised 3.9.2018, Accepted 9.9.2018

### ABSTRACT

The present study aims to investigate the side effect of the injection by Noristerat on some biochemistry parameter in women in Al-Diwaniya city by evaluate oxidative stress and antioxidant level and change in lipid profile in women that using contraceptive by injection Noristerat.

The results show that there is a significant increase in cholesterol, LDL and T.G, and a significant decrease in HDL in women who use contraception when compared with the group of women who do not use contraception. Also, the result points that there is increase significant in TOs and decrease significant in SOD, Cat, C.K and GSH in women who use contraception (Noristerat) when compared with the group of women without treatment contraception.

**Key words:** Noristerat , oxidative stress , lipid profile

### INTRODUCTION

Noristerat is drug used to prevent pregnancy, 200mg solution for intramuscular injection work by preventing ovulation (Gara *et al.*, 1991). Ingredients like benzyl benzoate, increase the risk of jaundice in newborn baby. It is usually given during the first 1-5days of period and injected slowly into a muscle is injectable type of contraceptive. It is intended as a short term method(8 weeks only) of contraceptive (Sharon *et al.*, 2012], contain a type of female sex hormone called progesterone, this hormone stops pregnant by three ways (Berenson *et al.*, 2009) the first preventing an egg being rele-ased from ovaries, second making the fluid (muc-us) in your cervix thicker, which makes it difficult for sperm to enter the womb and preventing the lining of womb thinking enough for an egg to grow in it (Berenson *et al.*, 2009]. This drug will not protect against sexually transmitted diseases and it is increase the risk of blood clot (Lopez *et al.*, 2014). Before taking this drug must check blood pressure and breast examination and nipple every month and avoided overweight or some heart diseases or migraine or had recently baby or blurred vision or any problems in hearing or speech, smell, taste, touch, swelling in legs, or shortness of breath, or any weak-ness, any liver diseases, diabetes, abnormal vaginal bleeding, have ever had an ectopic pregnancy and ovarian cysts (Saksit *et al.*, 2012].

This drug has not affect on to reduce the amount of milk produced which is an advantage if you wish to breast feed (Enyindan *et al.*, 2016). The Side effects of Noristerat show headache, change in vision, swelling of the legs or face or lips or all over the body, stabbing pain when the patient breathe numbness on the side or part of body, pain tightness of the chest, allergic reaction to this drug, dizziness, depressive moods, tender breasts, irregular bleeding and nausea (Ahmed *et al.*, 2015].

Many studies have noted a greater incidence of atherosclerosis and cardiovascular diseases in women using contraceptives and when Menopause. Progesterone may exercise Negative effect on fat metabolism progesterone only administered or combined with estrogen may Reducing plasma concentration of triglyceride and HDL cholesterol (Richmon *et al.*, 1973).

In women in the pre and postmenopausal period, stimulate the production of nitric oxide. And incr ease oxidative stress (Total oxidative stress) by decrease in antioxidant enzyme like SOD, CAT and CK [Richmon *et al.*, 1973].

Therefore, the present study was aimed to investigate the effect of Noristerat injection on the level of some serum biochemical parameters (SOD, Cat, GSH, C.K, TOs, CHO, LDL, HDL, T. G, T. protein, ALbumin and Uric acid) in women that using noristerat injection

### MATERIALS AND METHODS

A cross sectional study was conducted on the following groups during 1/6 /2017 - 13/10 /2017. The samples were obtained from in the General Afak Hospital center, samples divided in to 25 women with treatment with noristats that age  $37 \pm 0.97$  and weight  $85.4 \pm 0.96$ . And 25 women without treatment noristats age  $29.6 \pm 1.7$  and weight  $66.3 \pm 0.61$ . The laboratory work was carried out in the laboratory of research in the General Afak Hospital. Collection of samples, Samples could clot then centrifuged at 3000 Xg for 10 minutes. Biochemistry parameter tests were measured lipid profile CHO, LDL, HDL, T.G (Goldman *et al.*, 2008, Fossatin *et al.*, 1982, Bur-tis *et al.*, 1999, Misra 1974), SOD, Cat, C.k, TOs (Abedi 1974, Bais,1980, Erel 2005, Fossatin *et al.*, 1980) and Uric acid (Lenneruaset *et al.*, 1997).

**Bio statistical Analysis:** The data were analyzed using indepened t-samplle t-test in SPSS version 24.

## RESULTS AND DISCUSSION

**Lipid profile:** The statistical evaluation of Lipid profile show increased in both cholesterol, LDL and T.G and decrease in HDL in group women with injection Noristerat when compared with women group without injection noristerat  $P \leq 0.05$  show Table 1. The results of this learn indicated that there were colossal decreases within the degree of high density lipoprotein cholesterol (HDL-C) and increase low density lipoprotein ldl cholesterol (LDL-C). The intent of that's might be because of some medicinal drugs (noristerate) which causes inhibitor of (HMG-CoA) reductase enzyme and leads to that's state (Herrera *et al.*, 1988). Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors (Kruss 1982) or to cut back in lipoprotein lipase undertaking in CVA sufferers which results in diminish catabolism of (TG) into fatty acids and glycerol (Bitzur *et al.*, 2009] function of lipoprotein lipase pastime on lipoprotein metabolism and the fate of circulating triglycerides in pregnancy (Reaven *et al.*, 1996) or to action of some drugs which causes increase the hepatic receptor (ApoB-a hundred) which performs an foremost role in increase transport of LDL-C to hepatic tissue or may be because of insulin resistance in CVA sufferers which explanations abnormality in metabolism of lipids (Mendes 1983). Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal method (Nault *et al.*, 2017] Progesterone stimulates lipogenesis in adipose tissue with none develop in meals intake or serum insulin concentrations suggesting that progesterone will have a direct anabolic role in adipose tissue (Taryn *et al.*, 2008) Progesterone decreases the inhibiting the activity of both ATGL (Adipose triglyceride lipase (ATGL) (G0s2), genes in white adipose tissue (WAT) as skills targets for progesterone action in the course of the path addition to cut back adipose triglyceride lipase (Knopp *et al.*, 1994). The outcomes of this gain knowledge of indicate that there is large broaden within the degree of (TG) and the extent of very low density lipoprotein cholesterol (VLDL-C) the cause of that's could also be as a result of cut back in lipoprotein lipase endeavor excessive density lipoprotein ldl cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C), The cause of that's maybe due to some medicines or stains (simvastatin, pravastatin) which motives inhibitor of (HMG-CoA) reductase enzyme and leads to minimize the extent of total cholesterol (Osman *et al.*, 2017) or to scale down in lipoprotein lipase undertaking which ends up in cut back catabolism of (TG) into fatty acids and glycerol medications which explanations increase the hepatic receptor (ApoB-a hundred) which plays an major role in broaden transport of LDL-C to hepatic tissue. Noristerate induced hepatic lipase activity, growing the degradation of HDL, whereas, tend to reduce the develop in serum HDL and the lessen in serum LDL. These effects of drug contraception upon lipid profile rely upon

their biochemical structures whereas with pure noristerate effect do not alter the lipid metabolism and scale back HDL2, selectively in premenopausal females and this shrink associated with increase hepatic lipase endeavor. In women taken contraceptives containing overall noristerate improved plasma triglycerides and diminished plasma HDL above all HDL2. Estrogen is able of selling in vivo protecting actions, and discount of hepatic triglyceride lipase, which degrades HDL (excessive Density Lipoprotein), stimulating, accordingly, the construction of HDL ldl cholesterol and reducing the construction of LDL (Low Density Lipoprotein) ldl cholesterol, Progestins adversely affect carbohydrate and lipid metabolism as they cut back glucose tolerance by means of improved insulin resistance (Osman *et al.*, 2017).

**Antioxidant and oxidant:** In this study appear decrease in antioxidant enzyme SOD, CAT and C.K and decrease antioxidant non-enzyme GSH and increase oxidative stress TOs and Uric acid in group Women with injection by noristerat when compared with group Women without injection by noristerat show Table 2.

The decrements in antioxidant enzymes (SOD, Cat and C.K) due to increase oxidative stress the oxidative stress results of free radical (Chen *et al.*, 2012, Pincemail *et al.*, 2007). Free radicals are interaction with activity active sites of enzyme has effect on function and structure of enzyme therefore lower in activate of enzyme or due to the women who take contraception leads to menopause the menopause linked with increase oxidative stress and decrease antioxidant (Fijer *et al.*, 2016).

When occur menopause being release ROS and RNS therefore increase oxidative stress (Pincemail *et al.*, 2007). The GSH plays role in antioxidant detoxifies (Jendry *et al.*, 1992). The who take contraception (noristerat) that formation xenobiotic and toxic compound (Fallah *et al.*, 2011).

the xenobiotic and toxic compound reaction with GSH and converted to GS-SG or the decrease in GSH due to stop the menstrual cyclic in women with treatment by noristerat this leads to increase oxidative stress through product ROS and RNS that react with thiol group of GSH reduce and converted to GS-SG oxidant (Groote *et al.*, 2009). And increase TOs may be related to take contraception or to menopause this leads to increase TOS (Jendry *et al.*, 1992). Uric acid is marker to oxidative stress. In increase oxidative stress action on active-ited xanthine oxidase that is function on purine base metabolism and converted to interment then to uric acid (Groote *et al.*, 2009).

the correlation between period of Noristerat injection and another parameter show in Table 3. In this study appear signification correlation negative with HDL, SOD, CAT, C.K and GSH and positive correlation with Cholesterol, T.G, LDL, TOs and Uric acid may be related cause to increase injection lead to cumulative toxic compounds in body.

Table 1: The effect of Noristerat injection on lipid profile in women

Parameters	Women without injection by Noristerat (mean $\pm$ S.E)	Women with injection by Noristerat (mean $\pm$ S.E)	P-value $\leq$ 0.05
Cholestrol(mg/dl)	<b>151.7 <math>\pm</math> 3.4</b>	<b>202.4 <math>\pm</math> 4.6</b>	<b>S.g</b>
LDL (mg/dl)	<b>86.7 <math>\pm</math> 1.9</b>	<b>191.9 <math>\pm</math> 2.59</b>	<b>S.g</b>
HDL (mg/dl)	<b>41 <math>\pm</math> 1.3</b>	<b>21.2 <math>\pm</math> 1.48</b>	<b>S.g</b>
T.G (mg/dl)	<b>88 <math>\pm</math> 3.2</b>	<b>236 <math>\pm</math> 3.25</b>	<b>S.g</b>

Table 2: the effect of Noristerat injection on oxidant and antioxidant

Parameters	Women without injection by Noristerat (mean $\pm$ S.E)	Women with injection by Noristerat (mean $\pm$ S.E)	P-value $\leq$ 0.05
SOD (U/l)	<b>1.85 <math>\pm</math> 0.39</b>	<b>1.25 <math>\pm</math> 0.08</b>	<b>S.g</b>
CAT (U/l)	<b>1.9 <math>\pm</math> 0.055</b>	<b>1.28 <math>\pm</math> 0.07</b>	<b>S.g</b>
C.K (U/l)	<b>213 <math>\pm</math> 4.3</b>	<b>64.9 <math>\pm</math> 0.9</b>	<b>S.g</b>
GSH ( $\mu$ mol/L)	<b>12 <math>\pm</math> 0.319</b>	<b>6.9 <math>\pm</math> 0.25</b>	<b>S.g</b>
TOs ( $\mu$ mol/L)	<b>10.72 <math>\pm</math> 0.33</b>	<b>18.9 <math>\pm</math> 0.57</b>	<b>S.g</b>
Uric acid (mg/dl)	<b>5.28 <math>\pm</math> 0.429</b>	<b>11.8 <math>\pm</math> 0.18</b>	<b>S.g</b>

Table 3: the correlation between period of Noristerat injection and other parameter

Period of treatment	Parameter	Pearson correlation
	Cholesterol	0.979**
	LDL	0.901**
	HDL	-0.908**
	T.G	0.59
	SOD	-.984**
	CAT	-0.913**
	C.K	-0.896**
	GSH	-0.94**
	TOs	0.942**
	Uric acid	0.917**

\*\*Correlation is significant at the 0.01 level,

\*Correlation is significant at the 0.05 level

## REFERENCE

- Aebi, H. Catalase. In: methods of enzymatic analysis 2nd ed. Verlag chemie. weinheim, Germany Pp. 673-684 (1974).
- Ahmed, Inas Taha, Adellah Hamood Hussein, and Areej Talib. Lipid Profile Changes in Women in Reproductive Age Group Using Injectable Medroxyprogesterone Acetate Contraception. Medical Journal of Babylon 12(3): 802-816 (2015).
- Bais R. and J.R. Edwards, Increase creatine kinase activity associated with haemolysis, pathology Pp203-207 (1980).
- Berenson A.B., Rahman M. and G. Wilkinson, Effect of injectable and oral contraceptives on serum lipids. Obstetrics Gynecology 114(4): 786-94 (2009).
- Bitzur, R., Cohen, H., Kamari, Y., Shaish, A. and D. Harats, Triglycerides and HDL cholesterol. Diabetes care 32(suppl 2): S373-S377 (2009).
- Burtis, E.R. and W.B. Ashwood, Saunders Pp. 819-861 (1999).
- Chen, Jui Tung and Kazuhiko Kotani, Oral contraceptive therapy increases oxidative stress in premenopausal women. International Journal of Preventive Medicine 3(12): 893 (2012).
- De Groote, Donat, et al., Effects of oral contraception with ethinylestradiol and drospirenone on oxidative stress in women 18-35 years old. *Contraception* 80(2):187-193 (2009)
- Enyindah, Cosmos E. and Merry Jaja, Experience with Norethisterone Enanthate (Noristerat) at the University of Port Harcourt Teaching Hospital, Port Harcourt, South-ern Nigeria. British Journal of Medicine & Medical Research 18(3): 1-8 (2016).
- Erel O., A new automated colorimetric method for measuring total oxidant status. *Clinical Biochemistry* 38(12): 1103-11 (2005).
- Fallah, S., Sani, F. V. and M. Firoozrai, Effect of contraceptive pills on the activity status of the antioxidant enzymes glutathione peroxidase and superoxide dismutase in healthy subjects. *Contraception* 83(4): 385-389 (2011).
- Fijer, Ali N. and A.M. Lamia, Al-Mashhedy, Influence of Carnosine (E122) on oxidative stress status and the protective effect of vitamins C and E in male rats. *International Journal of PharmTech Research* 9(9): 261-270 (2016).
- Fossati P., Prencipe L. and G. Berti, Use of 3-5-di-chloro-2-hydroxybenzene sulfonic acid-4-aminophena zone chromogenic system in direct enzymic assay of uric acid in serum and urine. *Clin. Chem.* 26(2): 227-231 (1980).
- Fossati, Plero, and Lorenzo Prencipe, Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. *Clinical chemistry* 28(10): 2077-2080 (1982).
- Garza-Flores J., Menjivar M., Cardenas M., Reynoso M., Garcia G.A. and G. Perez Palacios, Further studies on the antigonadotropic mechanism of action of norethisterone. *The Journal of Steroid Biochemistry and Molecular Biology* 38(1): 89-93 (1991).
- Goldman, Lee and Dennis Arthur Ausiello, Eds. *Cecil medicine*. Vol. 702. Philadelphia^ ePA PA: Saunders Elsevier (2008).
- Herrera, E., Lasunción, M. A., Gomez-Coronado, D., Aranda, P., López-Luna, P. and I. Maier, American

- Journal of Obstetrics and Gynecology 158(6): 1575-1583 (1988).
- Jendryczko, A., Tomala, J. and P. Janosz, Effects of two lowdose oral contraceptives on erythrocyte superoxide dismutase, catalase and glutathione peroxidase activities. *Zentralblatt für Gynäkologie* 115 (11): 469-472 (1992).
- Knopp R.H., Zhu X. and B. Bonet, Effects of estrogens on lipoprotein metabolism and cardiovascular disease in women. *Atherosclerosis* 110: S83-91 (1994).
- Krauss R.M., Effect of progestational agents on serum lipids and lipoproteins. *J. Report Med.* 27: 503-510 (1982)
- Yadav B.K., Gupta R.K., Gyawali P., Shrestha R., Poudel B., Sigdel M. and B. Jha, *Korean J. Lab. Med.* 2011 31(2): 95-7 (2011).
- Lennernäs, H. and G. Fager, Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. *Clinical pharmacokinetics* 32 (5): 403-425 (1997).
- Lopez L.M., Grimes D.A. and K.F. Schulz, Steroidal contraceptives effect on bone fractures in women. *Cochrane Database Sys. Rev.* 6: CD0-06033 (2014). DOI: 10, 1002/1465185. CD00-6033. Pub5.
- Mendes A.M., Madon R.J. and D.J. Flint, Effects of cortisol and progesterone on insulin binding and lipogenesis in adipocytes from normal and diabetic rats. *J. Endocrinol.* 106: 225-231 (1985).
- Misra, H.P. and I. Fridovich, The role of Superoxide anion in the auto oxidation of epinephrine and a simple assay for Superoxide dismutase. *J. Biol. Chem.* 247: 3170-3175 (1972).
- Nault, R., Fader, K.A., Lydic, T. A. and T.R. Zacharewski, Lipidomic Evaluation of Aryl Hydrocarbon Receptor-Mediated Hepatic Steatosis in Male and Female Mice Elicited by 2,3,7,8-Tetrachlorodibenzo-p-dioxin. *Chem. Res. Toxicol.* 30(4): 1060-1075 (2017).
- Osman, N.N., E.J. Jambi and S.M. Bashaikh, Effect of Oral Contraceptive Pills on Oxidative Stress in Diabetic Rats. *International Journal of Pharmaceutical Research & Allied Sciences* 6(2): 171-185 (2017).
- Pincemail, Vanbelle S., Gaspard U., Collette G., Haleng J., Cheramy-Bien J.P., et al., Effect of different contraceptive methods on the oxidative stress status in women aged 40-48 years from the ELAN study in the province of Liege, Belgium. *Hum. Reprod.* 22: 2335-43 (2007).
- Reaven, G.M., Lithell, H. and L. Landsberg, Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. *New England Journal of Medicine* 334 (6): 374-382 (1996).
- Richmond, W., Preparation and properties of a cholesterol oxidase from *Nocardia* sp. and its application to the enzymatic assay of total cholesterol in serum. *Clinical chemistry* 19 (12): 1350-1356 (1973).
- Saksit Chanthai and Thaneetessiri, Analysis of Medroxyprogesterone Acetate in Human Plasma (2012).
- Sharon T. Cameron and Anna Glasier, Dewhurst's textbook of obstetrics and gynecology, 8th edition by Dr. Keith Edmon. Contraception and sterilization Pp.495-7 (2012)
- Lawrence Impey and Tim Child 4th edition. Obstetrics and gynaecology, contraception, Chapter 12, Pp. 98 (2012).
- Taryn F., *National Stroke Association.* 24: 78-89 (2008)